Hypoxia-inducible Factor-2 Regulates Vascular Tumorigenesis in Mice

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2008 May 21

PMID 18490920

Citations 86

Authors

Erinn B Rankin

Jennifer Rha

Travis L Unger

Chia H Wu

Heather P Shutt

Randall S Johnson

M Celeste Simon

Brian Keith

Volker H Haase

Affiliations

Soon will be listed here.

Abstract

The von Hippel-Lindau tumor suppressor pVHL regulates the stability of hypoxia-inducible factors (HIF)-1 and -2, oxygen-sensitive basic helix-loop-helix transcription factors, which mediate the hypoxic induction of angiogenic growth factors such as vascular endothelial growth factor. Loss of pVHL function results in constitutive activation of HIF-1 and HIF-2 and is associated with the development of highly vascularized tumors in multiple organs. We have used a conditional gene-targeting approach to investigate the relative contributions of HIF-1 and HIF-2 to VHL-associated vascular tumorigenesis in a mouse model of liver hemangiomas. Here we demonstrate genetically that conditional inactivation of HIF-2alpha suppressed the development of VHL-associated liver hemangiomas and that angiogenic gene expression in hepatocytes is predominantly regulated by HIF-2 and not by HIF-1. These findings suggest that HIF-2 is the dominant HIF in the pathogenesis of VHL-associated vascular tumors and that pharmacologic targeting of HIF-2 may be an effective strategy for their treatment.

Citing Articles

Toward a CRISPR-based mouse model of -deficient clear cell kidney cancer: Initial experience and lessons learned.

Stransky L, Gao W, Schmidt L, Bi K, Ricketts C, Ramesh V Proc Natl Acad Sci U S A. 2024; 121(41):e2408549121.

PMID: 39365820 PMC: 11474080. DOI: 10.1073/pnas.2408549121.

Total loss of gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2α activity.

Abu-Remaileh M, Persky N, Lee Y, Root D, Kaelin Jr W Proc Natl Acad Sci U S A. 2024; 121(40):e2410356121.

PMID: 39320914 PMC: 11459182. DOI: 10.1073/pnas.2410356121.

Molecular and phenotypic distinctions of macrophages in tolerant and susceptible to hypoxia rats.

Dzhalilova D, Kosyreva A, Lokhonina A, Tsvetkov I, Vishnyakova P, Makarova O PeerJ. 2023; 11:e16052.

PMID: 37842051 PMC: 10573310. DOI: 10.7717/peerj.16052.

Antiangiogenic Action of JZL184 on Endothelial Cells via Inhibition of VEGF Expression in Hypoxic Lung Cancer Cells.

Wittig F, Pannenberg L, Schwarz R, Bekeschus S, Ramer R, Hinz B Cells. 2023; 12(19).

PMID: 37830546 PMC: 10572003. DOI: 10.3390/cells12192332.

HIF1α and HIF2α immunoreactivity in epithelial tissue of primary and recurrent pterygium by immunohistochemical analysis.

Schoelles K, Kemper K, Martin G, Boehringer D, Brinks K, Mittelviefhaus H Int Ophthalmol. 2023; 43(12):4551-4562.

PMID: 37684398 PMC: 10724320. DOI: 10.1007/s10792-023-02855-3.

References

Kapitsinou P, Haase V . The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ. 2008; 15(4):650-9. PMC: 3799983. DOI: 10.1038/sj.cdd.4402313. View

Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M . The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev. 2004; 18(8):901-11. PMC: 395849. DOI: 10.1101/gad.291004. View

Gruber M, Hu C, Johnson R, Brown E, Keith B, Simon M . Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci U S A. 2007; 104(7):2301-6. PMC: 1892942. DOI: 10.1073/pnas.0608382104. View

Flamme I, Krieg M, Plate K . Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol. 1998; 153(1):25-9. PMC: 1852948. DOI: 10.1016/s0002-9440(10)65541-1. View

Rankin E, Biju M, Liu Q, Unger T, Rha J, Johnson R . Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007; 117(4):1068-77. PMC: 1838939. DOI: 10.1172/JCI30117. View

Gustafsson M, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J . Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell. 2005; 9(5):617-28. DOI: 10.1016/j.devcel.2005.09.010. View

Vortmeyer A, Gnarra J, Emmert-Buck M, Katz D, Linehan W, Oldfield E . von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol. 1997; 28(5):540-3. DOI: 10.1016/s0046-8177(97)90075-7. View

Rankin E, Higgins D, Walisser J, Johnson R, Bradfield C, Haase V . Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol. 2005; 25(8):3163-72. PMC: 1069599. DOI: 10.1128/MCB.25.8.3163-3172.2005. View

Biju M, Neumann A, Bensinger S, Johnson R, Turka L, Haase V . Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes. Mol Cell Biol. 2004; 24(20):9038-47. PMC: 517905. DOI: 10.1128/MCB.24.20.9038-9047.2004. View

10.

Maher E, Kaelin Jr W . von Hippel-Lindau disease. Medicine (Baltimore). 1997; 76(6):381-91. DOI: 10.1097/00005792-199711000-00001. View

11.

Rankin E, Giaccia A . The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008; 15(4):678-85. PMC: 3050610. DOI: 10.1038/cdd.2008.21. View

12.

Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H . Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell. 2006; 10(5):413-23. DOI: 10.1016/j.ccr.2006.08.026. View

13.

Rothhammer T, Bataille F, Spruss T, Eissner G, Bosserhoff A . Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene. 2006; 26(28):4158-70. DOI: 10.1038/sj.onc.1210182. View

14.

White P, Brestelli J, Kaestner K, Greenbaum L . Identification of transcriptional networks during liver regeneration. J Biol Chem. 2004; 280(5):3715-22. DOI: 10.1074/jbc.M410844200. View

15.

Haase V, Glickman J, Socolovsky M, Jaenisch R . Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A. 2001; 98(4):1583-8. PMC: 29300. DOI: 10.1073/pnas.98.4.1583. View

16.

Zatyka M, Fernandes da Silva N, Clifford S, Morris M, Wiesener M, Eckardt K . Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 2002; 62(13):3803-11. View

17.

Gijtenbeek J, Boots-Sprenger S, Franke B, Wesseling P, Jeuken J . Cyclin D1 genotype and expression in sporadic hemangioblastomas. J Neurooncol. 2005; 74(3):261-6. DOI: 10.1007/s11060-004-7326-z. View

18.

Bindra R, Vasselli J, Stearman R, Linehan W, Klausner R . VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 2002; 62(11):3014-9. View

19.

Raval R, Lau K, Tran M, Sowter H, Mandriota S, Li J . Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005; 25(13):5675-86. PMC: 1157001. DOI: 10.1128/MCB.25.13.5675-5686.2005. View

20.

McGrath F, Gibney R, Morris D, Owen D, Erb S . Case report: multiple hepatic and pulmonary haemangioblastomas--a new manifestation of von Hippel-Lindau disease. Clin Radiol. 1992; 45(1):37-9. DOI: 10.1016/s0009-9260(05)81467-9. View